The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
Open accessAbstract
Summary Background We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) completely protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever. Methods A combination of modified siRNAs targeting the ZEBOV L polymerase (EK-1 mod), viral protein (VP) 24 (VP24-1160 mod), and VP35 (VP35-855 mod) were formulated in SNALPs. A group of macaques (n=3) was given these pooled anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques (n=4) was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV. Findings Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection. Interpretation This complete postexposure protection against ZEBOV in non-human primates provides a model for the treatment of ZEBOV-induced haemorrhagic fever. These data show the potential of RNA interference as an effective postexposure treatment strategy for people infected with Ebola virus, and suggest that this strategy might also be useful for treatment of other emerging viral infections. Funding Defense Threat Reduction Agency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Self-citationHornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda
Towner, J. S., Sealy, T. K., Khristova, M. L., Albariño, C. G., Conlan, S., Reeder, S. A., Quan, P.-L., Lipkin, W. I., Downing, R., Tappero, J. W., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000212 · Cited by 599
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Self-citationDesign of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Self-citationThe Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3
Basler, C. F., Mikulasova, A., Martinez-Sobrido, L., Paragas, J., Mühlberger, E., Bray, M., Klenk, H.-D., Palese, P., & García-Sastre, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.14.7945-7956.2003 · Cited by 477
Ebola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear Accumulation
Reid, S. P., Leung, L. W., Hartman, A. L., Martinez, O., Shaw, M. L., Carbonnelle, C., Volchkov, V. E., Nichol, S. T., & Basler, C. F. (2006) · Journal of Virology · doi:10.1128/jvi.02349-05 · Cited by 463
Robbins, M., Judge, A., & MacLachlan, I. (2009) · Oligonucleotides · doi:10.1089/oli.2009.0180 · Cited by 449
Self-citationGeisbert, T. W., Hensley, L. E., Jahrling, P. B., Larsen, T., Geisbert, J. B., Paragas, J., Young, H. A., Fredeking, T. M., Rote, W. E., & Vlasuk, G. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15012-x · Cited by 382
Self-citationConfirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Self-citationSanchez, A., Kiley, M. P., Holloway, B. P., & Auperin, D. D. (1993) · Virus Research · doi:10.1016/0168-1702(93)90063-s · Cited by 318
A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA
Jeffs, L. B., Palmer, L. R., Ambegia, E. G., Giesbrecht, C., Ewanick, S., & MacLachlan, I. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1873-z · Cited by 307
Self-citationEffective Post-Exposure Treatment of Ebola Infection
Feldmann, H., Jones, S. M., Daddario-DiCaprio, K. M., Geisbert, J. B., Ströher, U., Grolla, A., Bray, M., Fritz, E. A., Fernando, L., Feldmann, F., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030002 · Cited by 288
Self-citationJahrling, P. B., Geisbert, T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., & Peters, C. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/514310 · Cited by 269
Self-citationGeisbert, T. W., Hensley, L. E., Kagan, E., Yu, E. Z., Geisbert, J. B., Daddario‐DiCaprio, K., Fritz, E. A., Jahrling, P. B., McClintock, K., Phelps, J. R., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/504267 · Cited by 254
Self-citationFiloviridae: Marburg and Ebola viruses.
Hazar, S., & Akan, E. (2000) · Cited by 253
Misinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation
Robbins, M., Judge, A., Ambegia, E., Choi, C., Yaworski, E., Palmer, L., McClintock, K., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.131 · Cited by 220
Self-citationMolecular Determinants of Ebola Virus Virulence in Mice
Ebihara, H., Takada, A., Kobasa, D., Jones, S., Neumann, G., Theriault, S., Bray, M., Feldmann, H., & Kawaoka, Y. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020073 · Cited by 214
Feldmann, H., & Klenk, H.-D. (1996) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60733-2 · Cited by 209
Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever
Hensley, L. E., Stevens, E. L., Yan, S.-C. B., Geisbert, J. B., Macias, W. L., Larsen, T., Daddario-DiCaprio, K. M., Cassell, G. H., Jahrling, P. B., & Geisbert, T. W. (2007) · The Journal of Infectious Diseases · doi:10.1086/520598 · Cited by 157
Self-citationWarfield, K. L., Swenson, D. L., Olinger, G. G., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020001 · Cited by 157
Combinatorial RNAi: A Winning Strategy for the Race Against Evolving Targets?
Grimm, D., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300116 · Cited by 153
Molecular Characterization of Guinea Pig-Adapted Variants of Ebola Virus
Volchkov, V. E., Chepurnov, A. A., Volchkova, V. A., Ternovoi, V. A., & Klenk, H. (2000) · Virology · doi:10.1006/viro.2000.0572 · Cited by 146
Prins, K. C., Delpeut, S., Leung, D. W., Reynard, O., Volchkova, V. A., Reid, S. P., Ramanan, P., Cardenas, W. B., Amarasinghe, G. K., Volchkov, V. E., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02459-09 · Cited by 146
Managing Potential Laboratory Exposure to Ebola Virus by Using a Patient Biocontainment Care Unit1
Kortepeter, M. G., Martin, J. W., Rusnak, J. M., Cieslak, T. J., Warfield, K. L., Anderson, E. L., & Ranadive, M. V. (2008) · Emerging infectious diseases · doi:10.3201/eid1406.071489 · Cited by 69
Misinterpreting the therapeutic effects of siRNA caused by immune stimulation
Robbins, M., Judge, A. D., Ambegia, E., Choi, C., Yaworski, E., Palmer, L., McClintock, K., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hgt.2008.131 · Cited by 41
Self-citationApplication of siRNA Against SARS in the Rhesus Macaque Model
Tang, Q., Li, B., Woodle, M. C., & Lu, P. Y. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-191-8_11 · Cited by 35
Yokota, T., Iijima, S., Kubodera, T., Ishii, K., Katakai, Y., Ageyama, N., Chen, Y., Lee, Y.-J., Unno, T., Nishina, K., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.182 · Cited by 27
Filovirus Pathogenesis in Nonhuman Primates
Geisbert, T. W., Jahrling, P. B., Larsen, T., Davis, K. J., & Hensley, L. E. (2002) · Defense Technical Information Center (DTIC) · doi:10.21236/ada421420 · Cited by 15
Self-citation
Cited by
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Feldmann, H., & Geisbert, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60667-8 · Cited by 1,374
Self-citationReversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Metadata
- Authors
- Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., Hensley, L. E., & MacLachlan, I.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 375
- Issue
- 9729
- Pages
- 1896-1905
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2125684318
- Cited by
- 463
- References
- 29
- FWCI
- 23.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.